| AJTR Copyright © 2009-All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711 |
Am J Translational Res 2010;2(4):368-380
Original Article
TSG101 exposure on the surface of HIV-1 infected cells: implications
for monoclonal antibody therapy for HIV/AIDS
Leyla Diaz, Hanwen Mao, Yu Zhou, Manu Kohli, Josephine Cassella, Zena Fesseha, Ke Weng, Hanson Chen,
Douty Bamba James D. Marks, Michael Goldblatt, Michael Kinch
Functional Genetics, Inc. 708 Quince Orchard Road, Gaithersburg, MD 20878 USA
Department of Anesthesiology, University of California, San Francisco, CA 94110 USA
Received July 8, 2010; accepted July 18, 2010; available online July 20, 2010
Abstract: HIV infection remains a major global public health problem, in part because of the ability of the virus to
elude antiretroviral therapies. Most conventional drugs were designed to directly target virus-encoded
mechanisms. However, there is increasing appreciation that certain host-encoded molecules are comparably
important for the viral life cycle and could therefore represent potential antiviral targets. Prominent among these is
TSG101, a cytoplasmic molecule that is “hijacked” by HIV and used to facilitate viral budding and release. In our
present report, we demonstrate that TSG101 is uniquely exposed on the surface of HIV-infected cells and is
available to antibody-based therapies. We also characterize the development of a monoclonal antibody, CB8-2,
which reduces virus production from infected cells. These studies demonstrate the potential of TSG101-directed
antibodies to combat HIV/AIDS. (AJTR1007002).
Key words: TSG101, HIV, monoclonal antibody, CB8-2, HIV/AIDS therapy
Full Text PDF
Address all correspondence to:
Leyla S. Diaz, PhD
708 Quince Orchard Road
Gaithersburg, MD 20878 USA
301-944-2323
E-mail: ldiaz@functional-genetics.com
Original Article
TSG101 exposure on the surface of HIV-1 infected cells: implications
for monoclonal antibody therapy for HIV/AIDS
Leyla Diaz, Hanwen Mao, Yu Zhou, Manu Kohli, Josephine Cassella, Zena Fesseha, Ke Weng, Hanson Chen,
Douty Bamba James D. Marks, Michael Goldblatt, Michael Kinch
Functional Genetics, Inc. 708 Quince Orchard Road, Gaithersburg, MD 20878 USA
Department of Anesthesiology, University of California, San Francisco, CA 94110 USA
Received July 8, 2010; accepted July 18, 2010; available online July 20, 2010
Abstract: HIV infection remains a major global public health problem, in part because of the ability of the virus to
elude antiretroviral therapies. Most conventional drugs were designed to directly target virus-encoded
mechanisms. However, there is increasing appreciation that certain host-encoded molecules are comparably
important for the viral life cycle and could therefore represent potential antiviral targets. Prominent among these is
TSG101, a cytoplasmic molecule that is “hijacked” by HIV and used to facilitate viral budding and release. In our
present report, we demonstrate that TSG101 is uniquely exposed on the surface of HIV-infected cells and is
available to antibody-based therapies. We also characterize the development of a monoclonal antibody, CB8-2,
which reduces virus production from infected cells. These studies demonstrate the potential of TSG101-directed
antibodies to combat HIV/AIDS. (AJTR1007002).
Key words: TSG101, HIV, monoclonal antibody, CB8-2, HIV/AIDS therapy
Full Text PDF
Address all correspondence to:
Leyla S. Diaz, PhD
708 Quince Orchard Road
Gaithersburg, MD 20878 USA
301-944-2323
E-mail: ldiaz@functional-genetics.com
 | |  | |  | |  | |  | |  | |  |